Cognivue Inc. in Victor recently named Fred Ma as its chief medical officer and senior vice president.
Ma’s nearly four-decade career spans global medical device and pharmaceutical development and commercialization, as well as advancing neurological disorder treatments, therapies and prevention as a neurosurgeon.
“Dr. Ma’s leadership has earned the highest respect among his clinical, industry and research peers worldwide,” said Tom O’Neill, president and CEO. “He has the rare ability to translate extensive medical and scientific knowledge into accessible insights and market-leading products. “We believe he will help take us to the next level with even better products and deeper relationships to come. His contributions in supporting existing customers and extending clinical validation through studies, manuscripts and more will be invaluable.”
Ma most recently served as president and chief operating officer of Innovative Health Sciences. He was chief medical officer for KORU Medical Systems, Innovacyn and GE Healthcare, and held leadership roles within Johnson & Johnson and Merck. Ma managed more than 100 new product developments with over 600 successful clinical trials and regulatory filings in the Americas, Europe, Africa and Asia-Pacific.
Before accepting his first industry position in 1990, Ma was a practicing neurosurgeon at the China-Japan Friendship Hospital in Beijing and the University of Tokyo Hospital, including tenures as attending physician and resident general chief. He received a Bachelor of Science/Doctor of Medicine degree from Capital University of Medical Sciences in Beijing, a Doctor of Medical Sciences from the University of Tokyo, and a doctorate in neuroscience from Rutgers University. He is board-certified in Japan and China in neurosurgery, functional neurosurgery and oncology.
“The passion shown by Dr. Ma for cognitive assessment and evaluation was evident from our first conversation,” O’Neill said. “Among his many accomplishments, he has been involved in drug research and clinical investigation for cognitive modulation on ADHD, Alzheimer’s and dementia, plus near infrared light therapy device development for TBI and PTSD. It’s hard to overstate his potential contributions as he becomes part of our fast-growing organization.”